Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 357,710,112
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.74
  • Price/Sales 4.61
  • Price/Cash Flow 15.85
  • Price/Book 4.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.15 +9.01%
on 02/05/18
148.32 -10.23%
on 01/17/18
-13.71 (-9.34%)
since 01/16/18
3-Month
122.15 +9.01%
on 02/05/18
148.32 -10.23%
on 01/17/18
-5.72 (-4.12%)
since 11/16/17
52-Week
118.05 +12.79%
on 02/17/17
148.32 -10.23%
on 01/17/18
+15.07 (+12.76%)
since 02/16/17

Most Recent Stories

More News
Stocks stretch winning streak to 6 days despite turbulence

NEW YORK (AP) — Stocks closed out their strongest week in five years Friday and have now recovered more than half of the losses they suffered in a plunge at the beginning of the month.

VFC : 74.64 (-11.08%)
CPB : 46.17 (-3.21%)
WFC : 59.95 (-0.12%)
JNJ : 133.15 (+1.46%)
HD : 186.97 (+0.92%)
PFE : 36.26 (+1.54%)
Markets Right Now: Stocks rise for the 6th straight day

NEW YORK (AP) — The latest on developments in financial markets (all times local):

JNJ : 133.15 (+1.46%)
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson

The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson (NYSE: JNJ) concerning possible violations of federal securities laws.

JNJ : 133.15 (+1.46%)
Watch for Johnson&Johnson to Potentially Pullback After Gaining 1.76% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $130.84 to a high of $133.85. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of...

JNJ : 133.15 (+1.46%)
After Yesterday's Rally of 1.76% Shares Could Potentially Pullback

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $130.84 to a high of $133.85. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of...

JNJ : 133.15 (+1.46%)
Johnson & Johnson Consumer Presents New Scientific Research At 2018 American Academy of Dermatology Annual Meeting

Reinforcing leadership in scientifically-driven skincare, Johnson & Johnson Consumer Inc. will present eight Scientific Posters at this year's American Academy of Dermatology (AAD) Annual Meeting in San...

JNJ : 133.15 (+1.46%)
Dow 30 Stock Roundup: Cisco Beats, Caterpillar January Sales up 34%

The Dow rebounded strongly over the first five trading days after entering correction territory last week.

CSCO : 44.33 (+0.57%)
V : 121.85 (-0.35%)
JNJ : 133.15 (+1.46%)
CAT : 156.29 (-2.31%)
XOM : 76.54 (+0.43%)
GS : 267.62 (-0.02%)
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan

AbbVie (ABBV) announces a 35% hike in its quarterly dividend along with the authorization of a new $10 billion share buyback program by the board.

JNJ : 133.15 (+1.46%)
ABBV : 118.60 (+3.22%)
RHHBY : 30.3000 (-0.36%)
AMGN : 183.55 (-0.03%)
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

MYL : 42.14 (+1.18%)
RDY : 34.74 (+0.03%)
JNJ : 133.15 (+1.46%)
TEVA : 20.90 (+0.43%)
Apalutamide (Johnson & Johnson) Drug Analysis 2018: An Orally Available Androgen Signaling Inhibitor - ResearchAndMarkets.com

The "Drug Analysis: Apalutamide" drug pipelines has been added to ResearchAndMarkets.com's offering.

JNJ : 133.15 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 136.42
1st Resistance Point 134.79
Last Price 133.15
1st Support Level 131.18
2nd Support Level 129.20

See More

52-Week High 148.32
Fibonacci 61.8% 136.76
Fibonacci 50% 133.18
Last Price 133.15
Fibonacci 38.2% 129.61
52-Week Low 118.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.